Credit Suisse 15/03/2010 1 Outperform $40.50 12.3%
Following news the company has received FDA approval for Hizentra the broker sees the subcutaneous immunoglobulin (SCIG) market the product is in as being worth as much as US$200m annually in sales.
It also notes the company has first mover advantage in the SCIG market, which should support margins in its view.
With the shares trading at a discount to their five-year average earnings multiple the broker retains its Outperform rating and $40.50 price target.
credit suisse - $40.50, page-24
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$311.70 |
Change
0.580(0.19%) |
Mkt cap ! $150.6B | |||
| Open | High | Low | Value | Volume |
| $308.37 | $311.70 | $307.33 | $411.6M | 1.374M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 55 | $310.93 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $311.74 | 904 | 1 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |